Answers are grounded in this paper and cite their sources.
EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D.
No takes yet. Share an insight, caveat, or question.
Kahl et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: